Trials Sponsors Conditions Drugs Pricing

Conditions

Psoriatic Arthritis TNF Ultrasound Assessment

Keywords

Psoriatic Arthritis Patients:ApremilastAdalimumab

Outcome Measures

Primary Outcomes (1)

Disease Activity Index for Psoriatic Arthritis
Assessment of disease activity in psoriatic arthritis patients by Disease Activity Index for Psoriatic Arthritis
3 months

Secondary Outcomes (2)

Health assessment questionnaire disability index
3 months
Psoriasis Area and Severity Index
3 months

Study Arms (2)

Group I

EXPERIMENTAL

consists of 30 PsA patients who will receive Adalimumab with methotrexate therapy for 3 months.

Drug: Adalimumab

Group II

EXPERIMENTAL

consists of 30 PsA patients who will receive Apremilast with methotrexate therapy for 3 months.

Drug: Apremilast

Interventions

AdalimumabDrug

PsA patients who will receive Adalimumab with methotrexate therapy for 3 months

Group I

ApremilastDrug

PsA patients who will receive Apremilast with methotrexate therapy for 3 months

Group II

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 70 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

This study will include 60 adult Psoriatic arthritis patients \>18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months.
Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains

Sponsors & Collaborators

Tanta University
Otherlead

Study Sites (1)

Tanta University

Tanta, Egypt

MennaAllah Elmalla, Assistant lecturerCONTACT+20 10 94422540 mennaallah.mohamed@med.tanta.edu.eg

MeSH Terms

Conditions

Arthritis, Psoriatic

Interventions

Adalimumabapremilast

Condition Hierarchy (Ancestors)

SpondylarthropathiesSpondylarthritisSpondylitisSpinal DiseasesBone DiseasesMusculoskeletal DiseasesArthritisJoint DiseasesPsoriasisSkin Diseases, PapulosquamousSkin Diseases

Central Study Contacts

MennaAllah Elmalla, Assistant lecturer

CONTACT

+20 10 94422540 mennaallah.mohamed@med.tanta.edu.eg

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant Lecturer of Rheumatology, Rehabilitation & Physical Medicine

Study Record Dates

First Submitted

January 29, 2026

First Posted

February 10, 2026

Study Start

December 30, 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

Apremilast and Adalimumab in Psoriatic Arthritis Patients

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Group I

Group II

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Group I

Group II

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations